Filipazzi V, Cattaneo M T, Rho B, Frontini L, D'Adda D, Isa L, Scapaticci R, Legnani W, Calzavara M P, Berni F
Department of Pulmonary Disease, S. Corona Hospital, Garbagnate, Italy.
Oncology. 1993;50(1):10-3. doi: 10.1159/000227139.
Forty-seven patients with stage III nonsmall cell lung cancer (NSCLC) were treated with the sequential administration of combination chemotherapy consisting of cisplatin, epirubicin and etoposide and of irradiation plus lonidamine. The response rate was 49% after chemotherapy with an improvement of 14% after radiation therapy and lonidamine. The median survival was around 15 months for responders and 9 months for nonresponders. Toxicity was moderate and acceptable. It is concluded that this schedule is active in the treatment of NSCLC.
47例Ⅲ期非小细胞肺癌（NSCLC）患者接受了顺铂、表柔比星和依托泊苷联合化疗序贯放疗加氯尼达明的治疗。化疗后的缓解率为49%，放疗加氯尼达明后缓解率提高了14%。缓解者的中位生存期约为15个月，未缓解者为9个月。毒性为中度且可接受。结论是该治疗方案对NSCLC治疗有效。
